Cover Image

Elagolix: How far can it go in the world of gynecology?

Saved in:

Bibliographic Details
Main Author:	Rachel B. Danis, M.D., M.S (Author)
Format:	Book
Published:	Elsevier, 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WHAT IS GOOD SCIENCE AND HOW FAR CAN IT GO?
by: Luis Fernando Aragón-Vargas
Published: (2017)

Paediatric surgery on the african continent: How far have we come; How far can we go?
by: Alp Numanoglu
Published: (2023)

Editorial: From Chronic Inflammation to Cancer: How Far Can Immunotherapy Go?
by: Xuefeng Li, et al.
Published: (2022)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
by: Catherine Boniface, M.D, et al.
Published: (2023)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
by: Kristof Chwalisz, M.D., Ph.D
Published: (2023)

Secret Diplomacy: How Far Can It Be Eliminated?
by: Reinsch, Paul S. (Paul Samuel), 1869-1923

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
by: David F. Archer, et al.
Published: (2020)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
by: Surrey ES, et al.
Published: (2020)

Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?
by: Sarah Allegra, et al.
Published: (2023)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
by: Ahmed Nader, et al.
Published: (2022)

Active commuting to school: How far is too far?
by: Moyna Niall M, et al.
Published: (2008)

Challenges in legitimizing further measures against smoking in jurisdictions with robust infrastructure for tobacco control: how far can the authorities allow themselves to go?
by: Karl Erik Lund, et al.
Published: (2024)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
by: Michael C. Snabes, M.D., Ph.D, et al.
Published: (2023)

Postpartum visits in the gynecological emergency room: How can we improve?
by: Alina Weissmann-Brenner, et al.
Published: (2020)

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
by: Neri M, et al.
Published: (2019)

Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
by: Mauricio S. Abrao, et al.
Published: (2021)

Best Pharmaceuticals for Children: How Far Have We Come?
by: Maryann Mazer-Amirshahi, MD, PharmD, et al.
Published: (2014)

GB and US: How far? How close?
by: John Atherton (dir.)
Published: (1986)

Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
by: Hikmat Abdel-Razeq
Published: (2021)

How Far Can Conversational Agents Contribute to IBD Patient Health Care-A Review of the Literature
by: Cláudia Pernencar, et al.
Published: (2022)

World Gynecologic Oncology Day: the use of Twitter to raise awareness of gynecologic cancersAJOG Global Reports at a Glance
by: Christina Uwins, MBChB, BSc Med Sci (Hons), et al.
Published: (2022)

How far have we come?
by: Priscilla Robinson, et al.
Published: (2015)

How Far is between Cancer and Health?
by: Chunsong HU, et al.
Published: (2019)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
by: Ahmed Abbas Suleiman, et al.
Published: (2020)

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
by: Juliawati Muhammad, et al.
Published: (2022)

The rise, progress, and phases of human slavery How it came into the world and how it shall be made to go out
by: O'Brien, James Bronterre, 1805-1864

Evidence-based policymaking is not like evidence-based medicine, so how far should you go to bridge the divide between evidence and policy?
by: Paul Cairney, et al.
Published: (2017)

Silk Fibroin Microneedles for Transdermal Drug Delivery: Where Do We Stand and How Far Can We Proceed?
by: Zhenzhen Qi, et al.
Published: (2023)

Neuro-Nutraceutical Polyphenols: How Far Are We?
by: Maria Teresa Gentile, et al.
Published: (2023)

How far are we from periodontal regeneration?
by: Patricio Smith
Published: (2015)

Is preimplantation genetic testing for aneuploidy (PGT-A) getting better? How can we know and how do we counsel our patients?
by: Richard J. Paulson, M.D., M.S
Published: (2023)

Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: A case report
by: Mariam Barseghyan, et al.
Published: (2023)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
by: Insa Winzenborg, et al.
Published: (2020)

"You Can't Go to the Park, You Can't Go Here, You Can't Go There": Exploring Parental Experiences of COVID-19 and Its Impact on Their Children's Movement Behaviours
by: Negin A. Riazi, et al.
Published: (2021)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
by: Sven Stodtmann, et al.
Published: (2021)

How Intelligence Can Be a Solution to Consequential World Problems
Published: (2022)

How far does school effectiveness come from?
by: J. Bonifacio Barba Casillas
Published: (2018)

Pain Catastrophizing: How Far Have We Come
by: Katarina Simic, et al.
Published: (2024)

Going Mobile: How Mobile Personal Health Records Can Improve Health Care During Emergencies
by: Bouri, Nidhi, et al.
Published: (2014)

Despite various initiatives thus far can there be sustainable development for humanity?
by: Dokun Oyeshola
Published: (2020)